ELI LILLY AND COMPANY

NYSE: LLY (Eli Lilly and Company)

Kemas kini terakhir: semalam, 1:59AM

1,010.31

-4.18 (-0.41%)

  • 1H -0.41%
  • 5H -6.06%
  • 1B 9.30%
  • 6B 30.58%
  • Tahun Ke Tarikh 29.85%
  • 1T 25.73%
  • 5T 585.33%
Penutupan Terdahulu 1,014.49
Buka 1,023.84
Jumlah Dagangan 1,963,618
Purata Dagangan (3B) 3,818,366
Modal Pasaran 905,699,262,464
Harga / Pendapatan (P/E TTM) 49.50
Harga / Pendapatan (P/E Ke hadapan) 32.57
Harga / Jualan (P/S) 15.66
Harga / Buku (P/B) 38.88
Julat 52 Minggu
623.78 (-38%) — 1,111.99 (10%)
Tarikh Pendapatan 30 Oct 2025
Hasil Dividen (DY TTM) 0.15%
Margin Keuntungan 22.67%
Margin Operasi (TTM) 42.49%
EPS Cair (TTM) 12.27
Pertumbuhan Hasil Suku Tahunan (YOY) 45.20%
Pertumbuhan Pendapatan Suku Tahunan (YOY) 23.00%
Jumlah Hutang/Ekuiti (D/E MRQ) 243.61%
Nisbah Semasa (MRQ) 1.37
Aliran Tunai Operasi (OCF TTM) 9.32 B
Aliran Tunai Bebas Leveraj (LFCF TTM) -1.82 B
Pulangan Atas Aset (ROA TTM) 16.45%
Pulangan Atas Ekuiti (ROE TTM) 77.28%

Arah Aliran Pasaran

Jangka Pendek Jangka Sederhana
Industri Drug Manufacturers - General (US) Menaik Menurun
Drug Manufacturers - General (Global) Menaik Menurun
Stok Eli Lilly and Company Menaik Menaik

AISkor Stockmoo

-0.3
Konsensus Penganalisis 1.5
Aktiviti Orang Dalam -2.5
Volatiliti Harga -3.0
Purata Bergerak Teknikal 0.0
Osilator Teknikal 2.5
Purata -0.30

Saham Serupa

Stok Modal Pasaran DY P/E (TTM) P/B
LLY 906 B 0.15% 49.50 38.88
NVS 254 B 3.27% 18.08 5.79
NVO 209 B 2.34% 12.52 8.16
JNJ 487 B 0.61% 19.51 6.24
ABBV 404 B 1.43% 171.96 50.46
MRK 252 B 1.60% 13.36 4.90

Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
Sektor Healthcare
Industri Drug Manufacturers - General
Gaya Pelaburan Large Growth
% Dimiliki oleh Orang Dalam 0.16%
% Dimiliki oleh Institusi 83.96%

Pemilikan

Nama Tarikh Syer Dipegang
Lilly Endowment Inc 30 Sep 2025 95,492,993
Julat 52 Minggu
623.78 (-38%) — 1,111.99 (10%)
Julat Harga Sasaran
830.00 (-17%) — 1,500.00 (-99%)
Tinggi 1,500.00 (Citigroup, 48.47%) Beli
Median 1,127.00 (11.55%)
Rendah 830.00 (Berenberg, -17.85%) Pegang
Purata 1,126.58 (11.51%)
Jumlah 10 Beli, 2 Pegang
Harga Purata @ Panggilan 962.69
Syarikat Tarikh Harga Sasaran Panggilan Harga @ Panggilan
BMO Capital 04 Dec 2025 1,200.00 (18.78%) Beli 1,014.49
06 Nov 2025 1,100.00 (8.88%) Beli 937.44
Bernstein 24 Nov 2025 1,300.00 (28.67%) Beli 1,070.16
Morgan Stanley 24 Nov 2025 1,290.00 (27.68%) Beli 1,070.16
13 Nov 2025 1,171.00 (15.91%) Beli 1,022.87
Truist Securities 19 Nov 2025 1,182.00 (16.99%) Beli 1,049.60
JP Morgan 18 Nov 2025 1,150.00 (13.83%) Beli 1,030.05
16 Sep 2025 1,050.00 (3.93%) Beli 764.71
Citigroup 12 Nov 2025 1,500.00 (48.47%) Beli 1,017.78
Freedom Capital Markets 10 Nov 2025 950.00 (-5.97%) Pegang 966.64
Leerink Partners 10 Nov 2025 1,104.00 (9.27%) Beli 966.64
UBS 07 Nov 2025 1,080.00 (6.90%) Beli 924.37
Cantor Fitzgerald 31 Oct 2025 985.00 (-2.51%) Beli 862.86
Guggenheim 16 Oct 2025 948.00 (-6.17%) Beli 819.38
08 Oct 2025 948.00 (-6.17%) Beli 845.72
Berenberg 17 Sep 2025 830.00 (-17.85%) Pegang 760.13
Papar semua
Nama Purata Belian ($) Purata Jualan ($) Jumlah Net Jumlah Nilai Bersih ($)
LILLY ENDOWMENT INC - 1,096.68 -305,000 -332,870,728
Jumlah Keseluruhan Kuantiti Bersih -305,000
Jumlah Keseluruhan Nilai Bersih ($) -332,870,728
Purata Pembelian Keseluruhan ($) -
Purata Jualan Keseluruhan ($) 1,096.68
Nama Pemegang Tarikh Jenis Kuantiti Harga Nilai ($)
LILLY ENDOWMENT INC 25 Nov 2025 Jual (-) 15,632 1,109.94 17,350,582
LILLY ENDOWMENT INC 25 Nov 2025 Jual (-) 147,061 1,109.94 163,228,886
LILLY ENDOWMENT INC 24 Nov 2025 Jual (-) 142,307 1,070.16 152,291,259
  • 3M
Tarikh Jenis Butiran
03 Dec 2025 Pengumuman U.S. FDA approves expanded indication for Lilly's Jaypirca (pirtobrutinib), the first and only non-covalent (reversible) BTK inhibitor, for adults with relapsed or refractory CLL/SLL previously treated with a covalent BTK inhibitor
01 Dec 2025 CNBC Eli Lilly cuts cash prices of Zepbound weight loss drug vials on direct-to-consumer site
24 Nov 2025 Pengumuman Lilly to present data from two positive Phase 3 studies of Jaypirca (pirtobrutinib) in chronic lymphocytic leukemia at the 2025 American Society of Hematology (ASH) Annual Meeting
24 Nov 2025 Pengumuman Lilly to highlight progress across key programs in early and advanced hormone receptor-positive breast cancer at the 2025 San Antonio Breast Cancer Symposium
24 Nov 2025 CNBC Eli Lilly hits $1 trillion market value, a first in health care, as Novo Nordisk tumbles
19 Nov 2025 Pengumuman Lilly announces plans to open Lilly Gateway Labs site in Philadelphia
18 Nov 2025 Pengumuman Lilly to participate in Citi's 2025 Global Healthcare Conference
17 Nov 2025 CNBC Novo Nordisk cuts direct-to-consumer prices for Wegovy, Ozempic to $349 a month
10 Nov 2025 Pengumuman Queer Eye's Tan France helps unthread obesity bias as part of Zepbound's (tirzepatide) 'Changing the Thread Collection'
07 Nov 2025 CNBC Millions more Americans could access obesity drugs after Trump's deals with Eli Lilly, Novo Nordisk
07 Nov 2025 CNBC Here's how much weight loss drugs could cost you under Trump's deals with Eli Lilly, Novo Nordisk
06 Nov 2025 Pengumuman Lilly's selective amylin agonist, eloralintide, demonstrated meaningful weight loss and favorable tolerability in a Phase 2 study of adults with obesity or overweight
06 Nov 2025 Pengumuman Lilly and U.S. government agree to expand access to obesity medicines to millions of Americans
06 Nov 2025 CNBC Trump announces deals with Eli Lilly, Novo Nordisk to slash weight loss drug prices, offer some Medicare coverage
06 Nov 2025 CNBC Eli Lilly to start late-stage trials on amylin obesity drug after it shows up to 20% weight loss in study 
06 Nov 2025 Pengumuman Lilly announces two new Executive Committee members and expansion of leadership roles to prepare for next wave of growth
04 Nov 2025 CNBC Metsera says Novo Nordisk’s new up to $10 billion bid for obesity drugmaker is ‘superior’ to revised Pfizer offer
03 Nov 2025 Pengumuman Lilly plans to build a new $3 billion facility to boost oral medicine manufacturing capacity in Europe for patients worldwide
03 Nov 2025 CNBC Pfizer files second lawsuit against Novo Nordisk, Metsera in bidding war over obesity biotech
02 Nov 2025 CNBC Where the blockbuster weight loss drug market stands today — and what’s coming next
30 Oct 2025 CNBC Eli Lilly blows past estimates, hikes guidance as Zepbound and Mounjaro sales soar
30 Oct 2025 Pengumuman Lilly reports third-quarter 2025 financial results, highlights R&D pipeline momentum and raises 2025 guidance
29 Oct 2025 Pengumuman LillyDirect and Walmart Pharmacy launch first retail pick-up option with direct-to-consumer pricing for Zepbound
29 Oct 2025 Pengumuman Lilly announces more than $1.2 billion investment in Puerto Rico facility to boost oral medicine manufacturing capacity in the United States
29 Oct 2025 CNBC Eli Lilly, Walmart to offer first retail pickup option for discounted vials of weight loss drug Zepbound
28 Oct 2025 Pengumuman Lilly announces roster of Team USA athletes for the Olympic and Paralympic Games Milano Cortina 2026, pledges to translate U.S. Olympic and Paralympic milestones into meaningful community impact
28 Oct 2025 Pengumuman Lilly partners with NVIDIA to build the industry's most powerful AI supercomputer, supercharging medicine discovery and delivery for patients
28 Oct 2025 CNBC Eli Lilly, Nvidia partner to build supercomputer, AI factory for drug discovery and development
27 Oct 2025 Pengumuman Lilly declares fourth-quarter 2025 dividend
27 Oct 2025 Pengumuman Lilly Drafts Shaquille O'Neal to Raise Awareness for Moderate-to-Severe Obstructive Sleep Apnea
27 Oct 2025 Pengumuman Lilly's Omvoh (mirikizumab-mrkz) demonstrated early and sustained improvement in bowel urgency outcomes for patients with ulcerative colitis
27 Oct 2025 Pengumuman Lilly's Omvoh (mirikizumab-mrkz) approved by U.S. FDA as a single-injection maintenance regimen in adults with ulcerative colitis
24 Oct 2025 Pengumuman Lilly's baricitinib delivered near-complete scalp hair regrowth at one year for adolescents with severe alopecia areata in Phase 3 BRAVE-AA-PEDS trial
24 Oct 2025 Pengumuman Lilly's EBGLYSS (lebrikizumab-lbkz) delivered durable disease control when administered once every eight weeks in patients with moderate-to-severe atopic dermatitis
24 Oct 2025 Pengumuman Lilly to Acquire Adverum Biotechnologies
17 Oct 2025 CNBC Eli Lilly and Novo Nordisk stocks fall as Trump says he wants $150 price for GLP-1s
17 Oct 2025 Pengumuman Lilly's Verzenio® (abemaciclib) prolonged survival in HR+, HER2-, high-risk early breast cancer with two years of treatment
16 Oct 2025 Pengumuman Lilly confirms date and conference call for third-quarter 2025 financial results announcement
15 Oct 2025 Pengumuman Lilly's oral GLP-1, orforglipron, demonstrated superior glycemic control in two successful Phase 3 trials, reconfirming its potential as a foundational treatment in type 2 diabetes
13 Oct 2025 Pengumuman Lilly to present new clinical data for Verzenio (abemaciclib) and multiple novel pipeline programs at the 2025 European Society for Medical Oncology (ESMO) Annual Meeting
07 Oct 2025 Pengumuman Lilly's Omvoh (mirikizumab-mrkz) is the first and only IL-23p19 antagonist to show four years of sustained, corticosteroid-free comprehensive patient outcomes in ulcerative colitis
26 Sep 2025 Pengumuman Lilly opens newest Gateway Labs site in San Diego to boost local biotechnology ecosystem
25 Sep 2025 Pengumuman Lilly's Kisunla (donanemab) receives marketing authorization by European Commission for the treatment of early symptomatic Alzheimer's disease
25 Sep 2025 Pengumuman U.S. FDA approves Inluriyo (imlunestrant) for adults with ER+, HER2-, ESR1-mutated advanced or metastatic breast cancer
23 Sep 2025 Pengumuman Lilly plans to build a new $6.5 billion facility to manufacture active pharmaceutical ingredients in Texas
23 Sep 2025 CNBC Eli Lilly to build $6.5 billion Texas manufacturing facility for obesity pill, other drugs
22 Sep 2025 CNBC Pfizer boosts obesity drug prospects with $7.3 billion deal to buy Metsera
17 Sep 2025 Pengumuman Lilly's Mounjaro (tirzepatide), a GIP/GLP-1 dual receptor agonist, reduced A1C by an average of 2.2% in a Phase 3 trial of children and adolescents with type 2 diabetes
17 Sep 2025 Pengumuman Lilly's oral GLP-1, orforglipron, superior to oral semaglutide in head-to-head trial
17 Sep 2025 CNBC Eli Lilly pill outperforms Novo Nordisk’s oral drug in head-to-head diabetes trial
16 Sep 2025 Pengumuman Lilly's oral GLP-1, orforglipron, demonstrated meaningful weight loss and cardiometabolic improvements in complete ATTAIN-1 results published in The New England Journal of Medicine
16 Sep 2025 Pengumuman Lilly announces plans to build $5 billion manufacturing facility in Virginia
16 Sep 2025 CNBC Eli Lilly to build $5 billion Virginia facility to boost production of targeted cancer drugs, other treatments
12 Sep 2025 CNBC Eli Lilly, Novo Nordisk prepare to face off in the next obesity drug battleground
11 Sep 2025 Pengumuman Lilly to participate in Bernstein's 2nd Annual Healthcare Forum
11 Sep 2025 CNBC Health care inflation rises as patients, employers brace for biggest jump in health spending in 15 years
09 Sep 2025 Pengumuman Lilly launches TuneLab platform to give biotechnology companies access to AI-enabled drug discovery models built through over $1 billion in research investment
09 Sep 2025 Pengumuman Lilly launches new "Brain Health Matters" campaign in partnership with Julianne Moore, empowering the public to prioritize brain health
08 Sep 2025 Pengumuman Lilly's Jaypirca (pirtobrutinib), the first and only approved non-covalent (reversible) BTK inhibitor, significantly improved progression-free survival in patients with treatment-naïve CLL/SLL
Papar semua
Hasil Dividen (DY TTM) 0.15%
Purata Hasil Dividen 5T 1.10%
Nisbah Pembayaran 43.94%
Jangkaan Pembayaran Dividen Seterusnya Dec 2025
Tarikh EX Tarikh Pengumuman Tarikh Pembayaran Perincian
14 Feb 2025 09 Dec 2024 10 Mar 2025 1.5 Tunai
15 Nov 2024 28 Oct 2024 10 Dec 2024 1.3 Tunai
15 Aug 2024 24 Jun 2024 10 Sep 2024 1.3 Tunai
15 May 2024 06 May 2024 10 Jun 2024 1.3 Tunai
14 Feb 2024 08 Dec 2023 08 Mar 2024 1.3 Tunai
14 Nov 2023 01 Nov 2023 08 Dec 2023 1.13 Tunai
14 Aug 2023 26 Jun 2023 08 Sep 2023 1.13 Tunai
12 May 2023 01 May 2023 09 Jun 2023 1.13 Tunai
14 Feb 2023 12 Dec 2022 10 Mar 2023 1.13 Tunai
14 Nov 2022 17 Oct 2022 09 Dec 2022 0.98 Tunai
12 Aug 2022 27 Jun 2022 09 Sep 2022 0.98 Tunai
13 May 2022 02 May 2022 10 Jun 2022 0.98 Tunai
14 Feb 2022 13 Dec 2021 10 Mar 2022 0.98 Tunai
12 Nov 2021 18 Oct 2021 10 Dec 2021 0.85 Tunai
12 Aug 2021 29 Jun 2021 10 Sep 2021 0.85 Tunai
13 May 2021 03 May 2021 10 Jun 2021 0.85 Tunai
11 Feb 2021 14 Dec 2020 10 Mar 2021 0.85 Tunai
12 Nov 2020 19 Oct 2020 10 Dec 2020 0.74 Tunai
13 Aug 2020 15 Jul 2020 10 Sep 2020 0.74 Tunai
14 May 2020 04 May 2020 10 Jun 2020 0.74 Tunai
13 Feb 2020 16 Dec 2019 10 Mar 2020 0.74 Tunai
14 Nov 2019 22 Oct 2019 10 Dec 2019 0.645 Tunai
14 Aug 2019 20 Jun 2019 10 Sep 2019 0.645 Tunai
16 May 2019 07 May 2019 10 Jun 2019 0.645 Tunai
14 Feb 2019 19 Dec 2018 08 Mar 2019 0.645 Tunai
14 Nov 2018 16 Oct 2018 10 Dec 2018 0.5625 Tunai
14 Aug 2018 19 Jun 2018 10 Sep 2018 0.5625 Tunai
16 May 2018 07 May 2018 08 Jun 2018 0.5625 Tunai
14 Feb 2018 11 Dec 2017 09 Mar 2018 0.5625 Tunai
14 Nov 2017 16 Oct 2017 08 Dec 2017 0.52 Tunai
11 Aug 2017 19 Jun 2017 08 Sep 2017 0.52 Tunai
11 May 2017 01 May 2017 09 Jun 2017 0.52 Tunai
13 Feb 2017 12 Dec 2016 10 Mar 2017 0.52 Tunai
10 Nov 2016 17 Oct 2016 09 Dec 2016 0.51 Tunai
11 Aug 2016 20 Jun 2016 09 Sep 2016 0.51 Tunai
11 May 2016 02 May 2016 10 Jun 2016 0.51 Tunai
10 Feb 2016 08 Dec 2015 10 Mar 2016 0.51 Tunai
10 Nov 2015 19 Oct 2015 10 Dec 2015 0.5 Tunai
12 Aug 2015 15 Jun 2015 10 Sep 2015 0.5 Tunai
14 May 2015 04 May 2015 10 Jun 2015 0.5 Tunai
11 Feb 2015 15 Dec 2014 10 Mar 2015 0.5 Tunai
12 Nov 2014 20 Oct 2014 10 Dec 2014 0.49 Tunai
13 Aug 2014 16 Jun 2014 10 Sep 2014 0.49 Tunai
13 May 2014 05 May 2014 10 Jun 2014 0.49 Tunai
12 Feb 2014 16 Dec 2013 10 Mar 2014 0.49 Tunai
13 Nov 2013 21 Oct 2013 10 Dec 2013 0.49 Tunai
13 Aug 2013 18 Jun 2013 10 Sep 2013 0.49 Tunai
14 May 2013 03 May 2013 10 Jun 2013 0.49 Tunai
13 Feb 2013 17 Dec 2012 08 Mar 2013 0.49 Tunai
13 Nov 2012 15 Oct 2012 10 Dec 2012 0.49 Tunai
13 Aug 2012 19 Jun 2012 10 Sep 2012 0.49 Tunai
13 Feb 2012 12 Dec 2011 09 Mar 2012 0.49 Tunai
10 Nov 2011 17 Oct 2011 09 Dec 2011 0.49 Tunai
11 Aug 2011 20 Jun 2011 09 Sep 2011 0.49 Tunai
11 May 2011 18 Apr 2011 10 Jun 2011 0.49 Tunai
11 Feb 2011 13 Dec 2010 10 Mar 2011 0.49 Tunai
10 Nov 2010 18 Oct 2010 10 Dec 2010 0.49 Tunai
11 Aug 2010 21 Jun 2010 10 Sep 2010 0.49 Tunai
12 May 2010 19 Apr 2010 10 Jun 2010 0.49 Tunai
10 Feb 2010 14 Dec 2009 10 Mar 2010 0.49 Tunai
10 Nov 2009 19 Oct 2009 10 Dec 2009 0.49 Tunai
12 Aug 2009 22 Jun 2009 10 Sep 2009 0.49 Tunai
13 May 2009 20 Apr 2009 10 Jun 2009 0.49 Tunai
11 Feb 2009 15 Dec 2008 10 Mar 2009 0.49 Tunai
12 Nov 2008 20 Oct 2008 10 Dec 2008 0.47 Tunai
13 Aug 2008 20 Jun 2008 10 Sep 2008 0.47 Tunai
13 Feb 2008 17 Dec 2007 10 Mar 2008 0.47 Tunai
13 Nov 2007 15 Oct 2007 10 Dec 2007 0.425 Tunai
13 Aug 2007 21 Jun 2007 10 Sep 2007 0.425 Tunai
11 May 2007 16 Apr 2007 08 Jun 2007 0.425 Tunai
13 Feb 2007 18 Dec 2006 09 Mar 2007 0.425 Tunai
13 Nov 2006 16 Oct 2006 08 Dec 2006 0.4 Tunai
11 Aug 2006 26 Jun 2006 08 Sep 2006 0.4 Tunai
11 May 2006 24 Apr 2006 09 Jun 2006 0.4 Tunai
13 Feb 2006 19 Dec 2005 10 Mar 2006 0.4 Tunai
10 Nov 2005 17 Oct 2005 09 Dec 2005 0.38 Tunai
11 Aug 2005 24 Jun 2005 09 Sep 2005 0.38 Tunai
11 May 2005 18 Apr 2005 10 Jun 2005 0.38 Tunai
11 Feb 2005 20 Dec 2004 10 Mar 2005 0.38 Tunai
10 Nov 2004 18 Oct 2004 10 Dec 2004 0.355 Tunai
11 Aug 2004 28 Jun 2004 10 Sep 2004 0.355 Tunai
12 May 2004 19 Apr 2004 10 Jun 2004 0.355 Tunai
11 Feb 2004 15 Dec 2003 10 Mar 2004 0.355 Tunai
12 Nov 2003 20 Oct 2003 10 Dec 2003 0.335 Tunai
13 Aug 2003 23 Jun 2003 10 Sep 2003 0.335 Tunai
13 May 2003 28 Apr 2003 10 Jun 2003 0.335 Tunai
12 Feb 2003 16 Dec 2002 10 Mar 2003 0.335 Tunai
13 Nov 2002 21 Oct 2002 10 Dec 2002 0.31 Tunai
13 Aug 2002 24 Jun 2002 10 Sep 2002 0.31 Tunai
13 May 2002 15 Apr 2002 10 Jun 2002 0.31 Tunai
13 Feb 2002 17 Dec 2001 08 Mar 2002 0.31 Tunai
13 Nov 2001 15 Oct 2001 10 Dec 2001 0.28 Tunai
13 Aug 2001 25 Jun 2001 10 Sep 2001 0.28 Tunai
11 May 2001 16 Apr 2001 11 Jun 2001 0.28 Tunai
13 Feb 2001 18 Dec 2000 09 Mar 2001 0.28 Tunai
13 Nov 2000 16 Oct 2000 11 Dec 2000 0.26 Tunai
11 Aug 2000 26 Jun 2000 11 Sep 2000 0.26 Tunai
11 May 2000 17 Apr 2000 09 Jun 2000 0.26 Tunai
11 Feb 2000 20 Dec 1999 10 Mar 2000 0.26 Tunai
10 Nov 1999 18 Oct 1999 10 Dec 1999 0.23 Tunai
11 Aug 1999 19 Jul 1999 10 Sep 1999 0.23 Tunai
12 May 1999 19 Apr 1999 10 Jun 1999 0.23 Tunai
10 Feb 1999 21 Dec 1998 10 Mar 1999 0.23 Tunai
10 Nov 1998 20 Oct 1998 10 Dec 1998 0.2 Tunai
12 Aug 1998 20 Jul 1998 10 Sep 1998 0.2 Tunai
13 May 1998 20 Apr 1998 10 Jun 1998 0.2 Tunai
11 Feb 1998 15 Dec 1997 10 Mar 1998 0.2 Tunai
12 Nov 1997 15 Sep 1997 10 Dec 1997 0.2 Tunai
13 Aug 1997 21 Jul 1997 10 Sep 1997 0.36 Tunai
13 May 1997 21 Apr 1997 10 Jun 1997 0.36 Tunai
12 Feb 1997 16 Dec 1996 10 Mar 1997 0.36 Tunai
13 Nov 1996 21 Oct 1996 10 Dec 1996 0.3425 Tunai
13 Aug 1996 15 Jul 1996 10 Sep 1996 0.3425 Tunai
13 May 1996 15 Apr 1996 10 Jun 1996 0.3425 Tunai
13 Feb 1996 18 Dec 1995 11 Mar 1996 0.3425 Tunai
13 Nov 1995 17 Oct 1995 11 Dec 1995 0.685 Tunai
11 Aug 1995 17 Jul 1995 11 Sep 1995 0.645 Tunai
09 May 1995 17 Apr 1995 12 Jun 1995 0.645 Tunai
Papar semua

Hasil Dividen Tahunan

Tahun Dividen Tahunan ($) Kekerapan/Tahun Hasil %
2025 1.50 1 0.15
2024 5.20 4 0.67
2023 4.52 4 0.78
2022 3.92 4 1.07
2021 3.40 4 1.23
2020 2.96 4 1.75
2019 2.58 4 1.96
2018 2.25 4 1.94
2017 2.08 4 2.46
2016 2.04 4 2.77
2015 2.00 4 2.37
2014 1.96 4 2.84
2013 1.96 4 3.84
2012 1.47 3 2.98
2011 1.96 4 4.72
2010 1.96 4 5.59
2009 1.96 4 5.49
2008 1.41 3 3.50
2007 1.70 4 3.18
2006 1.60 4 3.07
2005 1.52 4 2.69
2004 1.42 4 2.50
2003 1.34 4 1.91
2002 1.24 4 1.95
2001 1.12 4 1.43
2000 1.04 4 1.12
1999 0.920 4 1.38
1998 0.800 4 0.90
1997 1.28 4 1.84
1996 1.37 4 3.75
1995 1.98 3 7.02
Papar semua

Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.

Portfolio

AI Templat

Peringatan harga anda

Profil Risiko

| | | | |
Konservatif
Sederhana Konservatif
Sederhana
Sederhana Agresif
Agresif
Margin Keselamatan (EP)
Keuntungan Separa (TP1)
Keuntungan Sasaran (TP2)
Kerugian Maksimum (SL)

Penafian: Perkara di atas adalah untuk tujuan ilustrasi sahaja dan BUKAN nasihat pelaburan. Dapatkan nasihat daripada penasihat kewangan yang berkelayakan.

Harga Masuk (EP)

Ambil Untung 1 (TP1)

Ambil Untung 2 (TP2)

Henti Rugi (SL)

Julat 52 Minggu
 
52WL
 
52WH
SL
EP
TP1
TP2

Semua harga peringatan berada dalam julat harga 52 minggu

Keuntungan Nyata -
Keuntungan Tidak Nyata -
Dividen Diterima 2025 -
Jumlah Untung -
Pulangan Purata -
Kuantiti (Beli) -
Purata Harga (Beli) -
Kuantiti (Jual) -
Purata Harga (Jual) -
Tiada saham yang memenuhi kriteria anda